financial guidance

The company said that contact between its sales reps and clinicians began to decline in March due to the COVID-19 pandemic, affecting mainly SelectMDx volumes.

Clinical test volume at the company is expected to grow 7 percent year over year but decreased significantly at the end of March due to the COVID-19 pandemic.

The company said the COVID-19 pandemic and resulting stay-at-home orders have led to a slowdown in testing service volumes in recent weeks.

Starting late March and into its fiscal fourth quarter, social distancing guidelines began significantly impacting test volume trends, the company said.

Approximately 80 percent of gross product placements in the quarter were associated with interest in COVID-19 testing, the firm said

The company said that its preliminary revenues are expected to be down almost 8 percent year over year due to the pandemic.

The company said that as the COVID-19 pandemic spread throughout the world, it saw a "significant reduction in customer activity" by late March.

The company said its sales team will serve healthcare providers by telephone and online until it's safe to return to the field.

The skin cancer diagnostics company said it delivered 37 percent more DecisionDx-Melanoma test results in Q4 2019 than in the previous year's fourth quarter.

More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.